Selecta Biosciences

Clinical-stage biopharmaceutical company developing targeted immunotherapies using its ImmTOR platform to induce immune tolerance. Publicly traded on NASDAQ (SELB). Technology enables patients to receive gene therapies and other biologics without immune rejection.

Location
Watertown, Massachusetts, USA
Founded
2007
Investors
1
Categories
biotech, immunotherapy, drug-delivery, gene-therapy, public-company

Investors

NameLocationTypeStagesPortfolio
Polaris PartnersUSbiotech-focused-33